S
Shailendra Handu
Researcher at All India Institute of Medical Sciences
Publications - 36
Citations - 921
Shailendra Handu is an academic researcher from All India Institute of Medical Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 26 publications receiving 595 citations. Previous affiliations of Shailendra Handu include Sharda University & Arabian Gulf University.
Papers
More filters
Journal ArticleDOI
Evaluation of the knowledge, attitude and practice of self-medication among first-year medical students.
TL;DR: Klassical knowledge about appropriate self-medication was poor, attitude towards self- medication was positive, and the practice of self-Medication was common and often inappropriate.
Journal ArticleDOI
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Rohitash Yadav,Jitendra Kumar Chaudhary,Neeraj Jain,Pankaj Kumar Chaudhary,Supriya Khanra,Puneet Dhamija,Ambika Sharma,Ashish Kumar,Shailendra Handu +8 more
TL;DR: In this paper, the authors focused on genomic organization, structural and non-structural protein components, and potential prospective molecular targets for development of therapeutic drugs, convalescent plasm therapy, and a myriad of potential vaccines to tackle SARS-CoV-2 infection.
Journal ArticleDOI
Influence of medical training on self-medication by students.
TL;DR: This cross-sectional study shows that senior medical students tend to have greater knowledge of appropriate self-medication, have a more confident as well as concerned attitude towards self-Medication, and tend to practice self- medication more often and appropriately.
Journal ArticleDOI
Belimumab: First targeted biological treatment for systemic lupus erythematosus.
Ashok Kumar Dubey,Shailendra Handu,Suparna Dubey,Prashant Sharma,K K Sharma,Qazi Mushtaq Ahmed +5 more
TL;DR: Clinical features of SLE range from mild involvement of skin and joints to severe debilitating complications at later stages, such as infections and problems of renal, cardiovascular, and central nervous system, which are responsible for considerable morbidity and mortality.
Journal ArticleDOI
Suvorexant: The first orexin receptor antagonist to treat insomnia.
TL;DR: Suvorexant appears to be suitable as a chronic therapy for insomnia, because of minimal physical dependence and the availability of this new drug as an effective and safe alternative is an important and welcome development in insomnia management.